<DOC>
	<DOC>NCT00578708</DOC>
	<brief_summary>The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.</brief_summary>
	<brief_title>Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER</brief_title>
	<detailed_description />
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Heart Septal Defects, Ventricular</mesh_term>
	<criteria>Patients with hemodynamically significant Perimembranous ventricular septal defects Patients &lt; 8 kg Supracristal ventricular septal defects Left ventricle to right atrium shunting Prolapse of the aortic valve Right to left shunting through the defect Perimembranous VSD with an aneurysm and multiple shunts which can not be successfully closed with one device Patients with &lt;2mm aortic rim Sepsis (local/generalized) Complex heart lesions such as atrioventricular canal defect or Tetralogy of Fallot. Patients who are ASA intolerant Unable to be followed for the duration of the clinical trial Inability to obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>membranous</keyword>
	<keyword>ventricular</keyword>
	<keyword>septal</keyword>
	<keyword>defect</keyword>
	<keyword>VSD</keyword>
</DOC>